Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy

Abstract

Targeted drug delivery is a precise and effective strategy in oncotherapy that can accurately deliver drugs to tumor cells or tissues to enhance their therapeutic effect and, meanwhile, weaken their undesirable side effects on normal cells or tissues. In this research field, a large number of researchers have achieved significant breakthroughs and advances in oncotherapy. Typically, nanocarriers as a promising drug delivery strategy can effectively deliver drugs to the tumor site through enhanced permeability and retention (EPR) effect-mediated passive targeting and various types of receptor-mediated active targeting, respectively. Herein, we review recent targeted drug delivery strategies and technologies for enhancing oncotherapy. In addition, we also review two mainstream drug delivery strategies, passive and active targeting, based on various nanocarriers for enhancing tumor therapy. Meanwhile, a comparison and combination of passive and active targeting are also carried out. Furthermore, we discuss the associated challenges of passive and active targeted drug delivery strategies and the prospects for further study.

Additive Cytotoxic and Colony-Formation Inhibitory Effects of Aspirin and Metformin on PI3KCA-Mutant Colorectal Cancer Cells

“…Finally, the concentrations of MET and ASP used are above the current therapeutic blood levels of these drugs in humans. Nevertheless, targeted drug delivery, using e.g., nanocarriers, may overcome this problem [64].…”

PIEZO Ion Channels in Cardiovascular Functions and Diseases

“…For example, peptide- and antibody-based targeting strategies are currently used in oncotherapy to deliver drugs to tumor cells or tissues. 188 Synthesizing antibody-drug conjugates consist of the antibody, which targets an antigen exposed at the cell surface, chemically linked to the active therapeutic agent, known as the warhead. However, this approach is currently limited to highly potent drugs, given the large size of antibodies that gives a low loading efficiency.…”

Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy

“…Although liposome nanocarriers have the advantages of low toxicity, good biocompatibility, and biodegradability, they are still restricted owing to the low drug load, difficulty in sterilization, leakage risk of encapsulating agents, and lack of colloidal stability. [ 49 ] Micelles are difficult to apply because of their poor biocompatibility, unstable structure, and poor chemical versatility. Meanwhile, biological NPs and inorganic nonmetallic NPs also have the problem of low loading capacity.…”